Search Result

Results for "

Rapamycin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	mTOR (25) Akt (2) Aminoacyl-tRNA Synthetase (1) Antibiotic (3) Apoptosis (6) Autophagy (17) Bacterial (8) Biochemical Assay Reagents (1) Calcium Channel (1) Drug Derivative (1) Drug Intermediate (3) Drug Metabolite (5) E1/E2/E3 Enzyme (1) Endogenous Metabolite (4) FAK (1) FKBP (13) Formyl Peptide Receptor (FPR) (1) Fungal (7) Isotope-Labeled Compounds (4) MALT1 (1) MEK (1) PI3K (2) PPAR (1) PROTACs (1) Reference Standards (3)
By Research Areas:	Cancer (41) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (8) Neurological Disease (5)

By Targets:

mTOR (25)

Akt (2)

Aminoacyl-tRNA Synthetase (1)

Antibiotic (3)

Apoptosis (6)

Autophagy (17)

Bacterial (8)

Biochemical Assay Reagents (1)

Calcium Channel (1)

Drug Derivative (1)

Drug Intermediate (3)

Drug Metabolite (5)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (4)

FAK (1)

FKBP (13)

Formyl Peptide Receptor (FPR) (1)

Fungal (7)

Isotope-Labeled Compounds (4)

MALT1 (1)

MEK (1)

PI3K (2)

PPAR (1)

PROTACs (1)

Reference Standards (3)

By Research Areas:

Cancer (41)

Cardiovascular Disease (1)

Infection (6)

Inflammation/Immunology (8)

Neurological Disease (5)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: mTOR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10219

*Rapamycin* Maximum Cited Publications 1126 Publications Verification Sirolimus; AY-22989; NSC 226080	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219R

Rapamycin (Standard) Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)	Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin (Standard) is the analytical standard of Rapamycin. This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219G

Rapamycin Sirolimus; AY-22989; NSC 226080	mTOR	Cancer
Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin is a potent and specific mTOR inhibitor .

HY-10219S

Rapamycin-d3 1 Publications Verification Sirolimus-d₃; AY-22989-d₃; NSC 226080-d₃	Isotope-Labeled Compounds mTOR FKBP Autophagy	Cancer
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219GL

Rapamycin (GMP Like) Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)	mTOR FKBP Fungal Autophagy	Cancer
Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin is a potent and specific mTOR inhibitor .

HY-10219S1

Rapamycin-13C,d3 Sirolimus-¹³C,d₃; AY-22989-¹³C,d₃ NSC 226080-¹³C,d₃	Isotope-Labeled Compounds mTOR FKBP Autophagy	Cancer
Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃; AY-22989- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) ^[1].Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-153511

Rapamycin analog-2	Others	Cancer
Rapamycin analog-2 (compound A) is a Rapamycin analog .

HY-W765245

Rapamycin-13C,d3-1 Sirolimus-¹³C,d₃-1; AY-22989-¹³C,d₃-1	Isotope-Labeled Compounds Fungal mTOR Bacterial Autophagy Endogenous Metabolite FKBP Antibiotic	Cancer
Rapamycin- ¹³C,d₃-1 (Sirolimus- ¹³C,d₃-1) is the deuterium labeled and ¹³C-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-123691

7-O-Demethyl rapamycin	Fungal	Infection Inflammation/Immunology Cancer
7-O-Demethyl rapamycin, a derivative of Rapamycin (HY-10219), has antifungal activity and immunosuppressant properties. 7-O-Demethyl rapamycin has useful tumor cell growth-inhibiting activity .

HY-133770

*Seco Rapamycin* ethyl ester**	Drug Metabolite	Others
Seco Rapamycin ethyl ester is an open-ring metabolite of Rapamycin derivative. Seco-rapamycin is reported not to affect the mTOR function .

HY-19555

Seco Rapamycin SecoRapamycin A	Drug Metabolite	Others
Seco Rapamycin (Secorapamycin A) is the ring-opened product of Rapamycin. Seco-rapamycin is reported not to affect the mTOR function .

HY-19555A

*Seco Rapamycin* sodium salt** SecoRapamycin A monosodium	Drug Metabolite	Others
Seco Rapamycin sodium salt is the ring-opened product of Rapamycin. Seco-rapamycin is reported not to affect the mTOR function.

HY-12424A

42-(2-Tetrazolyl)rapamycin	Drug Intermediate	Cancer
42-(2-Tetrazolyl)rapamycin is a proagent compound of a rapamycin analog extracted from patent US 20080171763 A1, Example 1. Rapamycin is a specific mTOR inhibitor.

HY-132003

*Wortmannin-Rapamycin* Conjugate 1**	Akt	Cancer
Wortmannin-Rapamycin Conjugate 1 (compound 7c) is a furan ring-opened derivative of wortmannin-rapamycin conjugate with potent antitumor activities and a fine water solubility. Wortmannin-Rapamycin Conjugate 1 can inhibit the AKT phosphorylation in the tumor and can be used for cancer research .

HY-139085A

XL388-C2-amide-PEG9-NH2 hydrochloride	Drug Intermediate	Cancer
XL388-C2-amide-PEG9-NH2 hydrochloride is an intermediate used in the synthesis of C26-linked Rapamycin analog .

HY-139085B

XL388-C2-amide-PEG9-NH2 TFA	Drug Intermediate	Cancer
XL388-C2-amide-PEG9-NH2 TFA is an intermediate used in the synthesis of C26-linked Rapamycin analog .

HY-130835

FKBP12 PROTAC RC32 RC32	PROTACs FKBP	Cancer
FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984) .

HY-12424

Zotarolimus 4 Publications Verification ABT-578; A 179578	Drug Derivative	Cardiovascular Disease Inflammation/Immunology Cancer
Zotarolimus (ABT-578) is a derivative of Rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis .

HY-106345

ILS-920	FKBP Calcium Channel	Neurological Disease Inflammation/Immunology
ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52 versus FKBP12 .

HY-136583

28-Epirapamycin	Drug Metabolite	Others
28-Epirapamycin is an impurity of Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells .

HY-10949

SMER3	E1/E2/E3 Enzyme	Cancer
SMER3, a Rapamycin enhancer, is a selective Skp1-Cullin-F-box (SCF) ^Met30 ubiquitin ligase inhibitor. SMER3 enhances Rapamycin's growth inhibitory effect by inhibition of SCF ^Met30 .

HY-153806

RapaBlock ZZY05-092	FKBP	Cancer
RapaBlock is a potent, non-immunosuppressive and brain-impermeable FKBP12 ligand .

HY-W781875

Sirolimus isomer C	mTOR	Cancer
Sirolimus isomer C is an impurity of Rapamycin (Sirolimus) (HY-10219) .

HY-18672

SMER18	Autophagy	Cancer
SMER18 is a small molecule enhancer of rapamycin which act as a mTOR-independent autophagy inducer.

HY-101920

Autophinib 5+ Cited Publications	Autophagy PI3K	Neurological Disease Cancer
Autophinib is a potent, selective autophagy inhibitor with IC₅₀s of 90 nM and 40 nM for starvation- and Rapamycin-induced autophagy, respectively. Autophinib is also an ATP competitive Vacuolar Protein Sorting 34 (VPS34) inhibitor with an IC₅₀ of 19 nM. Autophinib inhibits autophagy induced by starvation or Rapamycin by targeting VPS34 .

HY-19555AR

*Seco Rapamycin* sodium salt (Standard)** SecoRapamycin A monosodium (Standard)	Reference Standards Drug Metabolite	Others
Phenglutarimid (hydrochloride) (Standard) is the analytical standard of Phenglutarimid (hydrochloride). This product is intended for research and analytical applications. Phenglutarimid hydrochloride is an anticholinergic used as an antiparkinsonian agent.

HY-141805

MHY-1685	mTOR	Cancer
MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.

HY-13766

Timcodar VX-853	PPAR	Others
Timcodar is a macrolide agent, and studies have shown that during adipogenesis, timcodar can significantly inhibit fat accumulation, with an effect similar to that of rapamycin. However, unlike rapamycin, timcodar does not cause immunosuppression and glucose resistance. In addition, timcodar can effectively inhibit the adipogenic transcriptional regulators PPAR?? and C/EBP??, thereby inhibiting genes involved in fat accumulation. These studies lay the foundation for timcodar as a potential anti-obesity therapy, as obesity is becoming a global epidemic.

HY-122402

Umirolimus	Bacterial	Inflammation/Immunology
Umirolimus, a macrocyclic triene lactone Rapamycin derivative, is powerful immunosuppressant and anti-inflammatory agent. Umirolimus has highly lipophilicity and can be used agent-eluting stent (DES) applications .

HY-142003

27-O-Demethylrapamycin	Fungal	Infection
27-O-Demethylrapamycin, a Rapamycin (HY-10219) derivative, is an antifungal agent. 27-O-Demethylrapamycin inhibits Candida albicans, Saccharomyces cerevisiae, and Fusarium oxysporum .

HY-135445

Prolylrapamycin 21-NorRapamycin	Fungal	Infection
Prolylrapamycin (21-Norrapamycin) is the derivative of Rapamycin (HY-10219). Prolylrapamycin exhibits antifungal activity, that inhibits Candida albicans, Saccharomyces cerevisiae, and Fusarium oxysporum with MIC of 0.125-2 μg/mL .

HY-128340

Autogramin-2	Autophagy	Cancer
Autogramin-2 potently inhibits autophagy induced by either starvation (IC₅₀=0.27 μM) or mTORC1 inhibition (Rapamycin; IC₅₀=0.14 μM) .

HY-128339

Autogramin-1	Autophagy	Cancer
Autogramin-1 potently inhibits autophagy induced by either starvation (IC₅₀=0.17 μM) or mTORC1 inhibition (Rapamycin; IC₅₀=0.44 μM) .

HY-136660

PQR626	mTOR	Neurological Disease
PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant mTOR inhibitor, with an IC₅₀ and K_i of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders .

HY-124726

Aumitin	Autophagy	Neurological Disease Cancer
Aumitin is a diaminopyrimidine-based autophagy inhibitor which inhibits mitochondrial respiration by targeting complex I. Aumitin inhibits starvation- and rapamycin induced autophagy dose dependently with IC₅₀s of 0.12 μM and 0.24 μM, respectively .

HY-111373

RapaLink-1 5+ Cited Publications	mTOR Autophagy	Cancer
RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .

HY-111065

OXA-01	mTOR	Cancer
OXA-01 is a potent mTORC1 and mTORC2 inhibitor, with IC₅₀ values of 29 nM and 7 nM, respectively .

HY-W339757

Dioctanoylphosphatidic acid sodium	mTOR Endogenous Metabolite	Cancer
Dioctanoylphosphatidic acid sodium functions as a modulator of phagocyte respiratory burst, acts as a precursor to diacylglycerol and lysophosphatidic acid, and influences the phosphorylation of the mammalian target of rapamycin (mTOR) while enhancing the viability of gallbladder carcinoma cells treated with histone deacetylase inhibitors (HDACIs); it is derived from glycerophospholipid through the action of phospholipase D.

HY-10218

Everolimus 90+ Cited Publications RAD001; SDZ-RAD	mTOR FKBP Autophagy Apoptosis Bacterial	Cancer
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-149861

Mip-IN-1	Bacterial	Infection
Mip-IN-1（S,S-28i）is a new rapamycin-derived macrophage infectivity potentiator (Mip) inhibitor. Mip-IN-1 displays strong anti-enzymatic activity against the Mip proteins of Neisseria meningitidis and Neisseria gonorrhoeae and substantially improved the ability of macrophages to kill the bacteria .

HY-10218S

Everolimus-d4 RAD001-d₄; SDZ-RAD-d₄	mTOR FKBP Autophagy Apoptosis	Cancer
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-12652

AZD3147	mTOR	Cancer
AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC₅₀ value of 1.5 nM. AZD3147 also has a selective effect on PI3K .

HY-172789

mTOR inhibitor-27	mTOR Apoptosis	Cancer
mTOR inhibitor-27 (Compound 7e) is a mammalian target of rapamycin (mTOR) inhibitor with an IC₅₀ value of 5.47 μM. mTOR inhibitor-27 can induce tumor cell apoptosis and arrest the cell cycle in the S-phase, thereby inhibiting cancer cell growth. mTOR inhibitor-27 is promising for research of cancers, such as skin cancer .

HY-134904

RMC-6272 3 Publications Verification RM-006	mTOR	Cancer
RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors .

HY-W003943

6-Hydroxypyridin-3-ylboronic acid	Biochemical Assay Reagents	Infection
6-Hydroxypyridin-3-ylboronic acid is a heterocyclic building block, which can be used in the synthesis of non-nucleoside inhibitors of hepatitis C virus (HCV) RNA-dependent RNA polymerase nonstructural protein 5B (NS5B). 6-Hydroxypyridin-3-ylboronic acid has also been used in the synthesis of mammalian target of rapamycin (mTOR) inhibitors .

HY-10218R

Everolimus (Standard) RAD001 (Standard); SDZ-RAD (Standard)	Reference Standards mTOR FKBP Autophagy Apoptosis Bacterial	Cancer
Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-161509

PT-88	mTOR	Cancer
PT-88 is a highly selective inhibitor of mTOR (Mammalian target of rapamycin) (IC₅₀=1.2 nM). PT-88 inhibits both mTORC1 and mTORC2 complexes, both of which are active forms of mTOR protein kinases and are closely associated with cell growth, proliferation, and survival. PT-88 can be used to study the role of mTOR in tumorigenesis and development, especially in the treatment of breast cancer .

HY-P1122

Cyclosporin H 1 Publications Verification	Formyl Peptide Receptor (FPR)	Infection Inflammation/Immunology
Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.

HY-116191

WJD008	PI3K mTOR	Cancer
WJD008 is a potent dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor with antiproliferative and anticlonogenic activity in tumor cells and transformed cells with PIK3CA mutant. WJD008 inhibits kinase activity of PI3K α and mTOR and abrogates insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling cascade. WJD008 is promising for research of cancers .

HY-10218S1

Everolimus-13C2,d4 RAD001-¹³C₂,d₄; SDZ-RAD-¹³C₂,d₄	Isotope-Labeled Compounds Bacterial Autophagy FKBP mTOR Apoptosis	Cancer
Everolimus- ¹³C₂,d₄ (RAD001- ¹³C₂,d₄) is ¹³C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

Cat. No.	Product Name	Type

HY-10219G

Rapamycin (GMP) Sirolimus (GMP); AY-22989 (GMP); NSC 226080 (GMP)	Fluorescent Dye
Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin is a potent and specific mTOR inhibitor .

HY-10219GL

Rapamycin (GMP Like) Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)	Fluorescent Dye
Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin is a potent and specific mTOR inhibitor .

Cat. No.	Product Name	Type

HY-10219G

Rapamycin (GMP) Sirolimus (GMP); AY-22989 (GMP); NSC 226080 (GMP)	Biochemical Assay Reagents
Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin is a potent and specific mTOR inhibitor .

HY-10219GL

Rapamycin (GMP Like) Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)	Biochemical Assay Reagents
Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin is a potent and specific mTOR inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P1122

Cyclosporin H 1 Publications Verification	Formyl Peptide Receptor (FPR)	Infection Inflammation/Immunology
Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10219

*Rapamycin* 1125+ Cited Publications Sirolimus; AY-22989; NSC 226080	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Source classification Disease Research Disease Research Fields Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219R

Rapamycin (Standard) Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Antibiotics Source classification Disease Research Endogenous metabolite	Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Standard) is the analytical standard of Rapamycin. This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-142003

27-O-Demethylrapamycin	Structural Classification Natural Products Microorganisms Source classification	Fungal
27-O-Demethylrapamycin, a Rapamycin (HY-10219) derivative, is an antifungal agent. 27-O-Demethylrapamycin inhibits Candida albicans, Saccharomyces cerevisiae, and Fusarium oxysporum .

HY-135445

Prolylrapamycin 21-NorRapamycin	Structural Classification Natural Products Microorganisms Source classification	Fungal
Prolylrapamycin (21-Norrapamycin) is the derivative of Rapamycin (HY-10219). Prolylrapamycin exhibits antifungal activity, that inhibits Candida albicans, Saccharomyces cerevisiae, and Fusarium oxysporum with MIC of 0.125-2 μg/mL .

HY-N15267

Ovalitenone	Structural Classification Natural Products Millettia peguensis Ali Leguminosae Source classification Plants	FAK Akt mTOR
Ovalitenone is a flavonoid compound that can be isolated from the plant Millettia peguensis. It shows no cytotoxic effects on lung cancer H460 and A549 cells, but it significantly inhibits anchorage-independent growth, CSC-like phenotypes, colony formation, and the migration and invasion capabilities of cancer cells. Ovalitenone can significantly reduce the levels of N-cadherin, snail, and slug, while increasing E-cadherin, thus inhibiting the EMT pathway. Additionally, Ovalitenone suppresses the signaling pathways regulated by focal adhesion kinase (FAK), ATP-dependent tyrosine kinase (AKT), mammalian target of rapamycin (mTOR), and cell division cycle 42 (Cdc42) .

Cat. No.	Compare	Product Name	Species	Source

HY-P70403

	FKBP3 Protein, Human (His) rHuPeptidyl-prolyl cis-trans isomerase FKBP3/FKBP3, His; Peptidyl-prolyl cis-trans isomerase FKBP3; PPIase FKBP3; 25 kDa FK506-binding protein; 25 kDa FKBP; FKBP-25; FK506-binding protein 3; FKBP-3; Immunophilin FKBP25; Rapamycin-selective 25 kDa immunophilin; Rotamase; FKBP25	Human	E. coli
	FKBP3 is a member of the FK506 and rapamycin-binding protein (FKBP) family and serves as a receptor for the immunosuppressants FK506 and rapamycin, both of which inhibit two distinct cytoplasmic signaling pathways. T cell proliferation. In addition to serving as a receptor for these immunosuppressants, FKBP3, like other peptidyl prolyl cis-trans isomerases (PPIases), also functions to accelerate protein folding. FKBP3 Protein, Human (His) is the recombinant human-derived FKBP3 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10219S

Rapamycin-d3 1 Publications Verification
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219S1

Rapamycin-13C,d3
Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃; AY-22989- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) ^[1].Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-10218S

Everolimus-d4
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-W765245

Rapamycin-13C,d3-1
Rapamycin- ¹³C,d₃-1 (Sirolimus- ¹³C,d₃-1) is the deuterium labeled and ¹³C-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10218S1

Everolimus-13C2,d4

Everolimus- ¹³C₂,d₄ (RAD001- ¹³C₂,d₄) is ¹³C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80759

	mTOR Antibody MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-Rapamycin complex-associated protein 1; FKBP12-Rapamycin complex-associated protein; Mammalian target of Rapamycin; mTOR; Mechanistic tar	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	mTOR Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to mTOR.

HY-P80838

	Phospho-mTOR (Ser2481) Antibody MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-Rapamycin complex-associated protein 1; FKBP12-Rapamycin complex-associated protein; Mammalian target of Rapamycin; mTOR; Mechanistic tar	WB	Human, Mouse, Rat
	Phospho-mTOR (Ser2481) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-mTOR (Ser2481).

HY-P80837

	Phospho-mTOR (Ser2448) Antibody (YA171) MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-Rapamycin complex-associated protein 1; FKBP12-Rapamycin complex-associated protein; Mammalian target of Rapamycin; mTOR; Mechanistic tar	WB, IHC-P	Human, Mouse
	Phospho-mTOR (Ser2448) Antibody (YA171) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-mTOR (Ser2448).

HY-P86383

	Phospho-mTOR(Ser2448) Antibody (YA6075) MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-Rapamycin complex-associated protein 1; FKBP12-Rapamycin complex-associated protein; Mammalian target of Rapamycin; mTOR; Mechanistic tar	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-mTOR(Ser2448) Antibody (YA6075) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-mTOR(Ser2448).

HY-P86389

	mTOR Antibody (YA6081) MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-Rapamycin complex-associated protein 1; FKBP12-Rapamycin complex-associated protein; Mammalian target of Rapamycin; mTOR; Mechanistic tar	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	mTOR Antibody (YA6081) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to mTOR.

HY-P86211

	RICTOR Antibody (YA5903) Rapamycin-insensitive companion of mTOR; AVO3 homolog; hAVO3;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse
	RICTOR Antibody (YA5903) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RICTOR.

HY-P85353

	RICTOR Antibody (YA5045) RICTOR; KIAA1999; Rapamycin-insensitive companion of mTOR; AVO3 homolog; hAVO3	WB, IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Monkey
	RICTOR Antibody (YA5045) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to RICTOR.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Rapamycin

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products